ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766 · see citing works

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243 · see citing works

The consensus molecular subtypes of colorectal cancer

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · see citing works

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · see citing works

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · see citing works

Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer

Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722 · see citing works

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · see citing works

Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955 · see citing works

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study

Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · see citing works

Cell-free nucleic acids as biomarkers in cancer patients

Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897 · see citing works

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · see citing works

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · see citing works

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · see citing works

Liquid Biopsies: Genotyping Circulating Tumor DNA

Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210 · see citing works

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · see citing works

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164 · see citing works

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · see citing works

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · see citing works

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Nordlinger, B., Sørbye, H., Glimelius, B. L. G., Poston, G. J., Schlag, P. M., Rougier, P. R., Bechstein, W. O., Primrose, J. M., Walpole, E. T., Finch-Jones, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60455-9 · Cited by 1,938 · see citing works

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · see citing works

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · see citing works

Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

Cohen, S. J., Punt, C. J. A., Iannotti, N. O., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E. P., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,843 · see citing works

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Douillard, J., Siena, S., Cassidy, J., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,802 · see citing works

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · see citing works

FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial

Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · see citing works

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · see citing works

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Bokemeyer, C., Bondarenko, I., Makhson, A. M., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,629 · see citing works

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,509 · see citing works

Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507 · see citing works

Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy

Adam, R. A., Delvart, V., Pascal, G., Valeanu, A., Castaing, D., Azoulay, D., Giacchetti, S., Paule, B., Kunstlinger, F., Ghémard, O., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000141198.92114.f6 · Cited by 1,478 · see citing works

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431 · see citing works

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen

Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · see citing works

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

Nordlinger, B., Sørbye, H., Glimelius, B. L. G., Poston, G. J., Schlag, P. M., Rougier, P. R., Bechstein, W. O., Primrose, J. M., Walpole, E. T., Finch-Jones, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70447-9 · Cited by 1,313 · see citing works

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

Forshew, T., Murtaza, M., Parkinson, C., Gale, D. G., Tsui, D. W. Y., Kaper, F., Dawson, S., Piskorz, A., Jimenez‐Liñan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,298 · see citing works

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · see citing works

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest

Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241 · see citing works

Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure

Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gönen, M., Kemeny, N. E., Brennan, M. F., Blumgart, L. H., & D'Angelica, M. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0833 · Cited by 1,189 · see citing works

Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna

(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174 · see citing works

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167 · see citing works

Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial

Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · see citing works

FOLFOXIRI plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Treatment of Patients with Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study

Cremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · see citing works

Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases

Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H. R., Chidel, M. A., Pugh, T. J., Kane, M. A., Gaspar, L. E., & Schefter, T. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6386 · Cited by 1,082 · see citing works

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070 · see citing works

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062 · see citing works

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works

Strategies for Safer Liver Surgery and Partial Liver Transplantation

Clavien, P., Petrowsky, H., DeOliveira, M. L., & Graf, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra065156 · Cited by 1,016 · see citing works

Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer

Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005 · see citing works

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

Rougier, P. R., Cutsem, E. V., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J. A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 989 · see citing works

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

Folprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Lordick, F., Hartmann, J. T., Lang, H., Frilling, A., Stoehlmacher, J., Weitz, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70330-4 · Cited by 962 · see citing works

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial

Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960 · see citing works

Ramucirumab versus Placebo in Combination with Second-Line FOLFIRI in Patients with Metastatic Colorectal Carcinoma That Progressed during or after First-Line Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine (RAISE): A Randomised, Double-Blind, Multicentre, Phase 3 Study

Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · see citing works

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 940 · see citing works

A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939 · see citing works

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

de Gramont, A., Bosset, J.-F., Milan, C., Rougier, P. R., Bouché, O., Etienne, P.-L., Morvan, F., Louvet, C., Guillot, T., François, É., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 906 · see citing works

Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin

Elias, D. M., Lefèvre, J. H., Chevalier, J., Brouquet, A., Marchal, F., Classe, J., Ferron, G., Guilloit, J., Méeus, P., Goèré, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7160 · Cited by 877 · see citing works

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Cassidy, J., Clarke, S. J., Díaz‐Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S. L., Lichinitser, M., Yang, T., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 861 · see citing works

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Fuchs, C. S., Marshall, J. L., Mitchell, E. P., Wierzbicki, R. F., Ganju, V., Jeffery, M., Schulz, J. J., Richards, D., Soufi‐Mahjoubi, R., Wang, B. X., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 849 · see citing works

Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patients

Blomgren, H., Lax, I., Näslund, I., & Svanström, R. (1995) · Acta Oncologica · doi:10.3109/02841869509127197 · Cited by 846 · see citing works

Regorafenib plus Best Supportive Care versus Placebo plus Best Supportive Care in Asian Patients with Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Li, J., Qin, S., Xu, R., Yau, T. C. C., Ma, B., Pan, H., Xu, J., Bai, Y., Chi, Y., Wang, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70156-7 · Cited by 813 · see citing works

Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases

Rusthoven, K. E., Kavanagh, B. D., Cardenes, H. R., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W. A., Kane, M. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6329 · Cited by 806 · see citing works

OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

Tournigand, C., Cervantes, A. M. R., Figer, A., Lledo, G., Flesch, M., Buyse, M. E., Mineur, L., Carola, É., Etienne, P.-L., Rivera, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0106 · Cited by 802 · see citing works

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O. M., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 798 · see citing works

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789 · see citing works

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775 · see citing works

Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

Venderbosch, S., Nagtegaal, I. D., Maughan, T. S., Smith, C. G., Cheadle, J. P., Fisher, D., Kaplan, R., Quirke, P., Seymour, M. T., Richman, S. D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0332 · Cited by 772 · see citing works

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746 · see citing works

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739 · see citing works

Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · see citing works

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Thierry, A. R., Mouliere, F. C., Messaoudi, S. E., Mollévi, C., Lopez‐Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 681 · see citing works

Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer

Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673 · see citing works

Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors

Taylor, A., Primrose, J. M., Langeberg, W. J., Kelsh, Mowat, F. S., Alexander, D., Choti, M. A., Poston, G. J., & Kanas, G. (2012) · Clinical Epidemiology · doi:10.2147/clep.s34285 · Cited by 665 · see citing works

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

Cunningham, D., Láng, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D. B., Jonker, D. J., Osborne, S., Andre, N., Waterkamp, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70154-2 · Cited by 641 · see citing works

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 637 · see citing works

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.-L. R., Hecht, J. R., Yu, H., Oliner, K. S., & Go, W. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2473 · Cited by 632 · see citing works

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

Folprecht, G., Grothey, A. F., Alberts, S. R., Raab, H.-R., & Köhne, C.-H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi246 · Cited by 630 · see citing works

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Koopman, M., Antonini, N. F., Douma, J., Wals, J., Honkoop, A. H., Erdkamp, F., de Jong, R. S., Rodenburg, C. J., Vreugdenhil, G., Loosveld, O. J. L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61086-1 · Cited by 629 · see citing works

Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer

Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · see citing works

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

Cutsem, E. V., Nordlinger, B., Adam, R. A., Köhne, C., Pozzo, C., Poston, G. J., Ychou, M., & Rougier, P. R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.012 · Cited by 586 · see citing works

The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus

Adam, R. A., de Gramont, A., Figueras, J., Guthrie, A. J., Kokudo, N., Kunstlinger, F., Loyer, E. M., Poston, G. J., Rougier, P. R., Rubbia‐Brandt, L., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0121 · Cited by 584 · see citing works

Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

Mitry, E., Fields, A. L. A., Bleiberg, H., Labianca, R., Portier, G., Tu, D., Nitti, D., Torri, V., Elias, D., O'Callaghan, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3781 · Cited by 583 · see citing works

Diagnostic Imaging of Colorectal Liver Metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: A Meta-Analysis of Prospective Studies Including Patients Who Have Not Previously Undergone Treatment

Niekel, M., Bipat, S., & Stoker, J. (2010) · Radiology · doi:10.1148/radiol.10100729 · Cited by 580 · see citing works

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Seymour, M., Maughan, T., Ledermann, J. A., Topham, C., James, R. D., Gwyther, S. J., Smith, D. B., Shepherd, S. F., Maraveyas, A., Ferry, D. R., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61087-3 · Cited by 559 · see citing works

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 535 · see citing works

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Tveit, K. M., Guren, T. K., Glimelius, B. L. G., Pfeiffer, P., Sørbye, H., Pyrhönen, S. O., Sigurdsson, F., Kure, E. H., Ikdahl, T., Skovlund, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0915 · Cited by 535 · see citing works

Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)

Lencioni, R. A., Crocetti, L., Cioni, R., Suh, R. D., Glenn, D. W., Regge, D., Helmberger, T. K., Gillams, A. R., Frilling, A., Ambrogi, M. C., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70155-4 · Cited by 532 · see citing works

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases

Zorzi, D., Laurent, A., Pawlik, T. M., Lauwers, G. Y., Vauthey, J.-N., & Abdalla, E. K. (2007) · British journal of surgery · doi:10.1002/bjs.5719 · Cited by 532 · see citing works

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Cutsem, E. V., Rivera, F., Berry, S. R., Kretzschmar, A., Michael, M., Bartolomeo, M. D., Mazier, M., Canon, J.-L., Georgoulias, V., Peeters, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp233 · Cited by 531 · see citing works

BRAFMutation in Metastatic Colorectal Cancer

Tol, J., Nagtegaal, I. D., & Punt, C. J. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904160 · Cited by 524 · see citing works

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Simkens, L. H. J., van Tinteren, H., May, A. M., ten Tije, A. J., Creemers, G., Loosveld, O. J. L., de Jongh, F. E., Erdkamp, F., Erjavec, Z., van der Torren, A. M. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62004-3 · Cited by 522 · see citing works

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · see citing works

Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution

Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 1× · see citing works

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Corcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507 · see citing works

Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study

Romero, A. M., Wunderink, W., Hussain, S. M., de Pooter, J. A., Heijmen, B. J. M., Nowak, P. J. C. M., Nuyttens, J. J. M. E., Brandwijk, R. P., Verhoef, C., IJzermans, J. N. M., et al. (2006) · Acta Oncologica · doi:10.1080/02841860600897934 · Cited by 498 · see citing works

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.

Levy, E., Piedbois, P., Buyse, M. E., Pignon, J., Rougier, P. R., RYAN, L. M., Hansen, R., Zee, B. C.-Y., Weinerman, B., Pater, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495 · see citing works

Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients

Taly, V., Pekin, D., Benhaïm, L., Kotsopoulos, S. K., Corre, D. L., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 494 · see citing works

Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases

Chun, Y. S. (2009) · JAMA · doi:10.1001/jama.2009.1755 · Cited by 494 · see citing works

Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations

Tsiatis, A. C., Norris-Kirby, A., Rich, R. G., Hafez, M. J., Gocke, C. D., Eshleman, J. R., & Murphy, K. M. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090188 · Cited by 488 · see citing works

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · see citing works

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

Papamichael, D., Audisio, R. A., Glimelius, B. L. G., de Gramont, A., Glynne‐Jones, R., Haller, D. G., Köhne, C. H., Rostoft, S., Lemmens, V. E. P. P., Mitry, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu253 · Cited by 475 · see citing works

Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases

Lee, M. T., Kim, J. J., Dinniwell, R. E., Brierley, J. D., Lockwood, G. A., Wong, R. K. S., Cummings, B., Ringash, J. G., Tse, R. V., Knox, J. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0600 · Cited by 474 · see citing works

Panitumumab versus Cetuximab in Patients with Chemotherapy-Refractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer (ASPECCT): A Randomised, Multicentre, Open-Label, Non-Inferiority Phase 3 Study

Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473 · see citing works

UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters

Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469 · see citing works

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Jhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · see citing works

Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance

Gormally, E., Caboux, É., Vineis, P., & Hainaut, P. L. (2007) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2006.11.002 · Cited by 444 · see citing works

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Ruers, T. J. M., Punt, C. J. A., van Coevorden, F., Pierie, J.-P. E. N., Rinkes, I. H. M. B., Ledermann, J. A., Poston, G. J., Bechstein, W. O., Lentz, M. A., Mauer, M. E. L., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds053 · Cited by 439 · see citing works

Prevalence and Heterogeneity of <i>KRAS, BRAF</i>, and <i>PIK3CA</i> Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

Baldus, S. E., Schaefer, K.-L., Engers, R., Hartleb, D., Stoecklein, N. H., & Gabbert, H. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2446 · Cited by 432 · see citing works

CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

Venook, A. P., Niedzwiecki, D., Lenz, H., Innocenti, F., Mahoney, M. R., O’Neil, B. H., Shaw, J. E., Polite, B. N., Höchster, H. S., Atkins, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba3 · Cited by 428 · see citing works

Phase II study on stereotactic body radiotherapy of colorectal metastases

Høyer, M., Roed, H., Hansen, A. T., Ohlhuis, L., Petersen, J. B., Nellemann, H. M., Berthelsen, A. K., Grau, C., Engelholm, S. A., & von der Maase, H. (2006) · Acta Oncologica · doi:10.1080/02841860600904854 · Cited by 427 · see citing works

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

Primrose, J. M., Falk, S. J., Finch-Jones, M., Valle, J. W., O'Reilly, D. A., Siriwardena, A. K., Hornbuckle, J., Peterson, M. C., Rees, M., Iveson, T. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70105-6 · Cited by 425 · see citing works

Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C. C., Herbst, F., & Gruenberger, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7679 · Cited by 423 · see citing works

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

Peters, G. J., Backus, H. H. J., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C. L., Smid, K., Lunec, J., Calvert, H., Marsh, S., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00082-0 · Cited by 419 · see citing works

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3148 · Cited by 415 · see citing works

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7723 · Cited by 413 · see citing works

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

Perrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M., Frattini, M., Riva, C., Andreola, S., Bajetta, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn541 · Cited by 410 · see citing works

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403 · see citing works

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

Cutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Dufour, P., Graeven, U., Lokich, J., Madajewicz, S., Maroun, J. A., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601676 · Cited by 402 · see citing works

Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes

Prades, J., Remue, E., Hoof, E. V., & Borràs, J. M. (2014) · Health Policy · doi:10.1016/j.healthpol.2014.09.006 · Cited by 402 · see citing works

Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

Hendlisz, A., den Eynde, M. V., Peeters, M., Maleux, G. A., Lambert, B., Vannoote, J., Keukeleire, K. D., Verslype, C., Defreyne, L., Cutsem, E. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.5643 · Cited by 402 · see citing works

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

Souglakos, J., Androulakis, N., Syrigos, K. N., Polyzos, A., Ziras, N., Athanasiadis, A., Kakolyris, S., Tsousis, S., Kouroussis, C., Vamvakas, L., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603011 · Cited by 400 · see citing works

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

Chibaudel, B., Maindrault‐Gœbel, F., Lledo, G., Mineur, L., André, T., Bennamoun, M., Mabro, M., Artru, P., Carola, É., Flesch, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4344 · Cited by 394 · see citing works

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases

Ye, L., Liu, T., Ren, L., Wei, Y., Zhu, D., Zai, S.-Y., Ye, Q., Yu, Y., Xu, B., Qin, X.-Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8308 · Cited by 392 · see citing works

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Seymour, M., Brown, S., Middleton, G., Maughan, T., Richman, S. D., Gwyther, S. J., Lowe, C., Seligmann, J., Wadsley, J., Maisey, N. R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 387 · see citing works

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

Mattos‐Arruda, L. D., Weigelt, B., Cortés, J., Won, H. H., Ng, C. K. Y., Nuciforo, P. G., Bidard, F., Aura, C. M., Saura, C., Peg, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu239 · Cited by 386 · see citing works

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 382 · see citing works

Frequency of <i>KRAS</i>, <i>BRAF</i>, and <i>NRAS</i> mutations in colorectal cancer

Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377 · see citing works

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

Gruenberger, T., Bridgewater, J. A., Chau, I., Alfonso, P., Rivoire, M. L., Mudan, S., Lasserre, S., Hermann, F., Waterkamp, D., & Adam, R. A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu580 · Cited by 356 · see citing works

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

Nordlinger, B., Cutsem, E. V., Gruenberger, T., Glimelius, B. L. G., Poston, G. J., Rougier, P. R., Sobrero, A. F., & Ychou, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn735 · Cited by 355 · see citing works

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Hazel, G. A. V., Heinemann, V., Sharma, N. K., Findlay, M. P. N., Ricke, J., Peeters, M., Perez, D., Robinson, B. A., Strickland, A. H., Ferguson, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1181 · Cited by 349 · see citing works

Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.

Fiorentini, G., Aliberti, C., Tilli, M., Mulazzani, L., Graziano, F., Giordani, P., Mambrini, A., Montagnani, F., Alessandroni, P., Catalano, V., et al. (2012) · PubMed · Cited by 329 · see citing works

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326 · see citing works

Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies

Goodman, K. A., Wiegner, E., Maturen, K. E., Zhang, Z., Mo, Q., Yang, G. P., Gibbs, I. C., Fisher, G. A., & Koong, A. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.020 · Cited by 326 · see citing works

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.173 · Cited by 319 · see citing works

Quantitative Detection of <i>EGFR</i> Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

Taniguchi, K., Uchida, J., Nishino, K., Kumagai, T., Okuyama, T., Okami, J., Higashiyama, M., Kodama, K., Imamura, F., & Kato, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1712 · Cited by 315 · see citing works

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S. A., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 310 · see citing works

Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

Kozloff, M. F., Yood, M. U., Berlin, J. D., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A. F., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0071 · Cited by 305 · see citing works

HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment

Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302 · see citing works

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T. S. K., Novello, S., O'Byrne, K. J., Stahel, R. A., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 300 · see citing works

KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291 · see citing works

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291 · see citing works

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

van Krieken, J. H., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F. T., Quirke, P., Fléjou, J., Hansen, T. P., Hertogh, G. D., et al. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0665-y · Cited by 289 · see citing works

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288 · see citing works

Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysis

Floriani, I., Torri, V., Rulli, E., Garavaglia, D., Compagnoni, A., Salvolini, L., & Giovagnoni, A. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22010 · Cited by 276 · see citing works

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group

Nordlinger, B., Cutsem, E. V., Rougier, P. R., Köhne, C.-H., Ychou, M., Sobrero, A. F., Adam, R. A., Arvidsson, D., Carrato, A., Georgoulias, V., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.017 · Cited by 272 · see citing works

Stereotactic radiotherapy of primary liver cancer and hepatic metastases

Wulf, J., Gückenberger, M., Hädinger, U., Oppitz, U., Mueller, G., Baier, K., & Flentje, M. P. (2006) · Acta Oncologica · doi:10.1080/02841860600904821 · Cited by 271 · see citing works

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

Folprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H.-R., Weitz, J., Lordick, F., Hartmann, J. T., Stoehlmacher-Williams, J., Lang, H., Trarbach, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu088 · Cited by 264 · see citing works

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Adams, R., Meade, A. M., Seymour, M., Wilson, R. H., Madi, A., Fisher, D. J., Kenny, S., Kay, E., Hodgkinson, E., Pope, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70102-4 · Cited by 263 · see citing works

Effects of Preanalytical Variables on the Detection of Proteins by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Tissue

Engel, K. B., & Moore, H. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0702-rair.1 · Cited by 263 · see citing works

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

Dancey, J. E., Dobbin, K. K., Groshen, S. G., Jessup, J. M., Hruszkewycz, A. H., Koehler, M. T., Parchment, R. E., Ratain, M. J., Shankar, L. K., Stadler, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2167 · Cited by 259 · see citing works

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256 · see citing works

Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line

Grothey, A. F., & Sargent, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4792 · Cited by 251 · see citing works

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial

Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C. A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00042-x · Cited by 251 · see citing works

A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin

Cao, C. Q., Yan, T. D., Black, D. A., & Morris, D. L. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0487-4 · Cited by 251 · see citing works

Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s Experiences

Kashima, M., Yamakado, K., Takaki, H., Kodama, H., Yamada, T., Uraki, J., & Nakatsuka, A. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.11.6408 · Cited by 248 · see citing works

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Peeters, M., Oliner, K. S., Parker, A. N., Siena, S., Cutsem, E. V., Huang, J., Humblet, Y., Laethem, J. V., André, T., Wiezorek, J. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1913 · Cited by 244 · see citing works

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Tabernero, J. M., Cutsem, E. V., Lakomý, R., Prausová, J., Ruff, P., Hazel, G. A. V., Moiseyenko, V. M., Ferry, D. R., McKendrick, J. J., Soussan-Lazard, K., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.013 · Cited by 243 · see citing works

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Monte, F. D., Cortesi, E., AMOROSO, D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70175-3 · Cited by 239 · see citing works

High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234 · see citing works

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 228 · see citing works

Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983

Tanis, E., Nordlinger, B., Mauer, M. E. L., Sørbye, H., van Coevorden, F., Gruenberger, T., Schlag, P. M., Punt, C. J. A., Ledermann, J. A., & Ruers, T. J. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.008 · Cited by 222 · see citing works

Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Piessevaux, H. H., Buyse, M. E., Schlichting, M., Cutsem, E. V., Bokemeyer, C., Heeger, S., & Tejpar, S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8532 · Cited by 219 · see citing works

Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer

Artale, S. A., Bianchi, A. S., Veronese, S. M., Gambi, V., Sarnataro, C., Gambacorta, M., Lauricella, C., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7286 · Cited by 216 · see citing works

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Díaz‐Rubio, E., Gómez‐España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., Rivera, F., Safont, M. J., de Prado, P. M., Gallén, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0249 · Cited by 210 · see citing works

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

Yaeger, R. D., Cercek, A., Chou, J. F., Sylvester, B. E., Kemeny, N. E., Hechtman, J. F., Ladanyi, M., Rosen, N. X., Weiser, M. R., Capanu, M., et al. (2014) · Cancer · doi:10.1002/cncr.28729 · Cited by 206 · see citing works

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

Wong, R., Cunningham, D., Barbáchano, Y., Saffery, C., Valle, J. W., Hickish, T., Mudan, S., Brown, G. M., Khan, A. Z., Wotherspoon, A. C., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq714 · Cited by 206 · see citing works

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

Hecht, J. R., Patnaik, A., Berlin, J. D., Venook, A. P., Malik, I. A., Tchekmedyian, S., Navale, L., Amado, R. G., & Meropol, N. J. (2007) · Cancer · doi:10.1002/cncr.22915 · Cited by 202 · see citing works

Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States

Turaga, K. K., Levine, E. A., Barone, R. M. E., Sticca, R. P., Petrelli, N. J., Lambert, L., Nash, G. M., Morse, M. A., Misih, R. A., Alexander, H. R., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3061-z · Cited by 194 · see citing works

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Cremolini, C., Loupakis, F., Antoniotti, C., Lonardi, S., Masi, G., Salvatore, L., Cortesi, E., Tomasello, G., Spadi, R., Zaniboni, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv112 · Cited by 192 · see citing works

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

Maughan, T., James, R., Kerr, D., Ledermann, J. A., Seymour, M., Topham, C., McArdle, C. S., Cain, D., & Stephens, R. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12461-0 · Cited by 191 · see citing works

Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial

Scorsetti, M., Arcangeli, S., Tozzi, A., Comito, T., Alongi, F., Navarria, P., Mancosu, P., Reggiori, G., Fogliata, A., Torzilli, G., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.021 · Cited by 190 · see citing works

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

Garufi, C., Torsello, A., Tumolo, S., Ettorre, G. M., Zeuli, M., Campanella, C., Vennarecci, G., Mottolese, M., Sperduti, I., & Cognetti, F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605940 · Cited by 186 · see citing works

Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases?

Adam, R. A., Bhangui, P., Poston, G. J., Mirza, D., Nuzzo, G., Barroso, E., Ijzermans, J., Hubert, C., Ruers, T. J. M., Capussotti, L., et al. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181fcf3e3 · Cited by 184 · see citing works

Analysis of KRAS / NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181 · see citing works

BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes

Domingo, E., Niessen, R. C., Oliveíra, C., Alhopuro, P., Moutinho, C., Espín, E., Armengol, M., Sijmons, R. H., Kleibeuker, J. H., Seruca, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208569 · Cited by 178 · see citing works

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

Oliveíra, C., Velho, S., Moutinho, C., Ferreira, A. M., Preto, A., Domingo, E., Capelinha, A. F., Duval, A., Hamelin, R., Machado, J. C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209758 · Cited by 177 · see citing works

Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing

Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Höefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 175 · see citing works

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 175 · see citing works

KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

Valtorta, E., Misale, S., Sartore‐Bianchi, A., Nagtegaal, I. D., Paraf, F., Lauricella, C., Dimartino, V., Hobor, S., Jacobs, B., Ercolani, C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28106 · Cited by 175 · see citing works

Left-Liver Hypertrophy After Therapeutic Right-Liver Radioembolization Is Substantial but Less Than After Portal Vein Embolization

Garlipp, B., de Baère, T., Damm, R., Irmscher, R., Buskirk, M. V., Stübs, P., Deschamps, F., Meyer, F. P., Seidensticker, R., Mohnike, K., et al. (2013) · Hepatology · doi:10.1002/hep.26947 · Cited by 166 · see citing works

Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer

Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Коваленко, С. Г., Beshay, V., Young, M., McArthur, G. A., Boussioutas, A., & Dobrovic, A. (2007) · Familial Cancer · doi:10.1007/s10689-007-9124-1 · Cited by 165 · see citing works

Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis

Juo, Y., Johnston, F. M., Zhang, D., Juo, H. H., Wang, H., Pappou, E. P., Yu, T., Easwaran, H., Baylin, S. B., van Engeland, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu149 · Cited by 165 · see citing works

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M. M., Chua, T. C., Pelz, J. O. W., Baratti, D., Baumgartner, J. M., Berri, R. N., Bretcha-Boix, P., et al. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23728 · Cited by 163 · see citing works

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015

Köhne, C.-H., Grève, J. D., Hartmann, J. T., Láng, I., Vergauwe, P. L., Becker, K., Braumann, D., Joosens, E. J., Müller, L., Janssens, J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm544 · Cited by 162 · see citing works

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

Okines, A. F. C., del Puerto, O., Cunningham, D., Chau, I., Cutsem, E. V., Saltz, L. B., & Cassidy, J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605259 · Cited by 162 · see citing works

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Karapetis, C. S., Jonker, D. J., Daneshmand, M., Hanson, J. E. L., O'Callaghan, C. J., Marginean, C. E., Zalcberg, J. R., Simes, J. R., Moore, M. J., Tebbutt, N. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0606 · Cited by 158 · see citing works

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Passardi, A., Nanni, O., Tassinari, D., Turci, D., Cavanna, L., Fontana, A., Ruscelli, S., Mucciarini, C., Lorusso, V., Ragazzini, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv130 · Cited by 158 · see citing works

Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis

Martin, R. C. G., Scoggins, C. R., Schreeder, M. T., Rilling, W. S., Laing, C. J., Tatum, C. M., Kelly, L. R., Mónaco, R. G., Sharma, V. R., Crocenzi, T. S., et al. (2015) · Cancer · doi:10.1002/cncr.29534 · Cited by 157 · see citing works

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Cremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 156 · see citing works

KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis

Cejas, P., López-Gómez, M., Aguayo, C., Madero, R., de Castro, J., Belda-Iniesta, C., Barriuso, J., Moreno, V., Larrauri, J., López, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008199 · Cited by 154 · see citing works

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

Étienne-Grimaldi, M.-C., Formento, J., Francoual, M., François, É., Formento, P., Renée, N., Laurent‐Puig, P., Chazal, M., Benchimol, D., Delpéro, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4906 · Cited by 151 · see citing works

Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review

Maffione, A. M., Lopci, E., Bluemel, C., Giammarile, F., Herrmann, K., & Rubello, D. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2930-4 · Cited by 150 · see citing works

Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography–Guided High-Dose-Rate Brachytherapy

Ricke, J., Mohnike, K., Pech, M., Seidensticker, M., Rühl, R., Wieners, G., Gaffke, G., Kropf, S., Felix, R., & Wust, P. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.026 · Cited by 143 · see citing works

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)

Koeberle, D., Betticher, D. C., von Moos, R., Dietrich, D., Brauchli, P., Baertschi, D., Matter-Walstra, K. W., Winterhalder, R., Borner, M., Anchisi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv011 · Cited by 141 · see citing works

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · see citing works

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · see citing works

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Glynne‐Jones, R., Wyrwicz, L. S., Tiret, E., Brown, G. M., Rödel, C. M., Cervantes, A. M. R., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,062 · see citing works

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · see citing works

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,709 · see citing works

Comprehensive review of targeted therapy for colorectal cancer

Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159 · see citing works

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956 · see citing works

Colorectal cancer liver metastases – a population-based study on incidence, management and survival

Engstrand, J., Nilsson, H., Strömberg, C., Jonas, E., & Freedman, J. (2018) · BMC Cancer · doi:10.1186/s12885-017-3925-x · Cited by 902 · see citing works

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H., Venook, A. P., Heinemann, V., Cutsem, E. V., Pignon, J., Tabernero, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 837 · see citing works

From tumour heterogeneity to advances in precision treatment of colorectal cancer

Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654 · see citing works

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682 · see citing works

Early‐onset colorectal cancer in young individuals

Mauri, G., Bianchi, A. S., Russo, A. G., Marsoni, S., Bardelli, A., & Siena, S. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12417 · Cited by 639 · see citing works

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573 · see citing works

Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update

Izzo, F., Granata, V., Grassi, R., Fusco, R., Palaia, R., Delrio, P., Carrafiello, G., Azoulay, D., Petrillo, A., & Curley, S. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0337 · Cited by 581 · see citing works

Liver metastases

Tsilimigras, D. I., Brodt, P., Clavien, P., Muschel, R. J., D'Angelica, M. I., Endo, I., Parks, R. W., Doyle, M. B., de Santibáñes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 576 · see citing works

DNA mismatch repair in cancer

Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 559 · see citing works

Clinical management of metastatic colorectal cancer in the era of precision medicine

Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. M., & Cervantes, A. M. R. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 537 · see citing works

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

Li, W., Zhou, C., Yu, L., Hou, Z., Liu, H., Kong, L.-H., Xu, Y., He, J., Jin, L., Ou, Q., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2249762 · Cited by 486 · see citing works

Colorectal Cancer Immunotherapy: Options and Strategies

Johdi, N. A., & SUKOR, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 457 · see citing works

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424 · see citing works

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Siena, S., Bartolomeo, M. D., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Élez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 432 · see citing works

Exploring immunotherapy in colorectal cancer

Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355 · see citing works

Gut microbiome and its role in colorectal cancer

Reberšek, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-09054-2 · Cited by 365 · see citing works

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Finn, R. S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347 · see citing works

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

Vidal, J., Muinelo, L., Dalmases, A., Jones, F. S., Edelstein, D. L., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344 · see citing works

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): A multicentre, open-label, phase 3, randomised, controlled trial

Cremolini, C., Antoniotti, C., Rossini, D., Lonardi, S., Loupakis, F., Pietrantonio, F., Bordonaro, R., Latiano, T. P., Tamburini, E., Santini, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30862-9 · Cited by 334 · see citing works

Treatment sequencing in metastatic colorectal cancer

Modest, D. P., Pant, S., & Bianchi, A. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 328 · see citing works

Biomarker-guided therapy for colorectal cancer: strength in complexity

Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320 · see citing works

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes

Loree, J. M., Pereira, A. A. L., Lam, M. S., Willauer, A. N., Raghav, K. P. S., Dasari, A. N., Morris, V. K., Advani, S., Menter, D. G., Eng, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2484 · Cited by 316 · see citing works

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy

Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 303 · see citing works

Young-onset colorectal cancer

Spaander, M. C. W., Zauber, A. G., Syngal, S., Blaser, M. J., Sung, J. J. �., You, Y. N., & Kuipers, E. J. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00432-7 · Cited by 299 · see citing works

Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Stewart, C. L., Warner, S. G., Ito, K., Raoof, M., Wu, G. X., Kessler, J., Kim, J. Y., & Fong, Y. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.08.004 · Cited by 291 · see citing works

Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?

Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123733 · Cited by 262 · see citing works

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes

Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 278 · see citing works

Colorectal liver metastases: Current management and future perspectives

Martin, J. L., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S. A., Cheow, H. K., Duckworth, A., Heister, P. M., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 279 · see citing works

Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance

Tuomisto, A., Mäkinen, M. J., & Väyrynen, J. P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i31.4383 · Cited by 279 · see citing works

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study

Xu, J., Kim, T. W., Shen, L., Sriuranpong, V., Pan, H., Xu, R., Guo, W., Han, S., Liu, T., Park, Y. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3245 · Cited by 266 · see citing works

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., Li, W., Xu, N., Lin, L.-Z., Wu, Q., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3183 · Cited by 237 · see citing works

Determinants of metastatic competency in colorectal cancer

Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 257 · see citing works

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

Garlan, F., Laurent‐Puig, P., Sefrioui, D., Siauve, N., Didelot, A., Sarafan‐Vasseur, N., Michel, P., Perkins, G., Mulot, C., Blons, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3155 · Cited by 250 · see citing works

Modern therapeutic approaches for the treatment of malignant liver tumours

Petrowsky, H., Fritsch, R., Gückenberger, M., Oliveira, M. L. D., Dutkowski, P., & Clavien, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0314-8 · Cited by 248 · see citing works

Pathological Features and Prognostication in Colorectal Cancer

Chen, K., Collins, G. P., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 248 · see citing works

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

Siena, S., Bianchi, A. S., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F. M., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 249 · see citing works

S3-Leitlinie – Kolorektales Karzinom

Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 242 · see citing works

Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

Chiorean, E. G., Nandakumar, G., Fadelu, T. A., Temin, S., Alarcon-Rozas, A. E., Bejarano, S., Croitoru, A. E., Grover, S., Lohar, P. V., Odhiambo, A. O., et al. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00367 · Cited by 244 · see citing works

Precision oncology in metastatic colorectal cancer — from biology to medicine

Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 238 · see citing works

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial

Pfeiffer, P., Yilmaz, M., Möller, S., Zitnjak, D., Krogh, M., Petersen, L. N., Poulsen, L. Ø., Winther, S. B., Thomsen, K. G., & Qvortrup, C. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30827-7 · Cited by 232 · see citing works

Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches

Saman, H. T., Raza, S. S., Shahab Uddin, M. S., & Rasul, K. I. (2020) · Cancers · doi:10.3390/cancers12051172 · Cited by 244 · see citing works

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

Cremolini, C., Antoniotti, C., Stein, A., Bendell, J. C., Gruenberger, T., Rossini, D., Masi, G., Ongaro, E., Hurwitz, H. I., Falcone, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01225 · Cited by 236 · see citing works

Colorectal liver metastases: An update on multidisciplinary approach

Chow, F. C.-L., & Chok, K. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i2.150 · Cited by 232 · see citing works

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225 · see citing works

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial

Andre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00064-4 · Cited by 209 · see citing works

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224 · see citing works

General insight into cancer: An overview of colorectal cancer (Review)

Alzahrani, S. M., Doghaither, H. A. A., & Al-Ghafari, A. B. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2433 · Cited by 242 · see citing works

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hofheinz, R., Fokas, E., Benhaïm, L., Price, T. J., Arnold, D., Beets‐Tan, R. G. H., Guren, M. G., Hospers, G. A. P., Lonardi, S., Nagtegaal, I. D., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.528 · Cited by 235 · see citing works

Expert Consensus Document on Pulmonary Metastasectomy

Handy, J. R., Bremner, R. M., Crocenzi, T. S., Detterbeck, F. C., Fernando, H. C., Fidias, P. M., Firestone, S., Johnstone, C. A., Lanuti, M. D., Litle, V. R., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.10.028 · Cited by 205 · see citing works

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

García‐Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z. A., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 202 · see citing works

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer

Oliveira, A., Bretes, L., & Furtado, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00396 · Cited by 199 · see citing works

Hepatic metastasis from colorectal cancer

Kow, A. W. C. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.08.06 · Cited by 199 · see citing works

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Stintzing, S., Wirapati, P., Lenz, H., Neureiter, D., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al‐Batran, S., Heintges, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz387 · Cited by 196 · see citing works

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Modest, D. P., Martens, U. M., Riera‐Knorrenschild, J., Greeve, J. C., Florschütz, A., Weßendorf, S., Ettrich, T. J., Kanzler, S., Nörenberg, D., Ricke, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01340 · Cited by 192 · see citing works

Survival improvement for patients with metastatic colorectal cancer over twenty years

Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192 · see citing works

Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

Bonney, G. K., Chew, C. A. Z., Lodge, P. A., Hubbard, J. M., Halazun, K. J., Trunečka, P., Muiesan, P., Mirza, D. F., Isaac, J., Laing, R. W., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00219-3 · Cited by 191 · see citing works

Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study

Tie, J., Wang, Y., Cohen, J. D., Li, L., Hong, W., Christie, M., Wong, H., Kosmider, S., Wong, R., Thomson, B. N. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003620 · Cited by 184 · see citing works

CIRSE Standards of Practice on Thermal Ablation of Liver Tumours

Crocetti, L., de Baère, T., Pereira, P. L., & Tarantino, F. P. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02471-z · Cited by 181 · see citing works

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

Kuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30425-4 · Cited by 180 · see citing works

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

Bachet, J., Bouché, O., Taı̈eb, J., Dubreuil, O., Garcia‐Larnicol, M., Meurisse, A., Normand, C., Gornet, J., Artru, P., Louafi, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy061 · Cited by 178 · see citing works

International Journal of Clinical Oncology

(2013) · International Journal of Clinical Oncology · doi:10.1007/10147.1437-7772 · Cited by 175 · see citing works

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173 · see citing works

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178 · see citing works

Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway

Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00814 · Cited by 173 · see citing works

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities

Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0719-1 · Cited by 170 · see citing works

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Markham, M. J., WACHTER, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C., Galindo, C. R., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 176 · see citing works

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

Rosen, L. S., Jacobs, I. A., & Burkes, R. L. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0518-1 · Cited by 167 · see citing works

Making Meaningful Clinical Use of Biomarkers

Selleck, M. J., Senthil, M., & Wall, N. R. (2017) · Biomarker Insights · doi:10.1177/1177271917715236 · Cited by 162 · see citing works

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

Auclin, É., Zaanan, A., Vernerey, D., Douard, R., Gallois, C., Laurent‐Puig, P., Bonnetain, F., & Taı̈eb, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx030 · Cited by 155 · see citing works

The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases

Bălăcescu, O., Sur, D. G., Cainap, C. I., Vișan, S., Cruceriu, D., Manzat-Saplacan, R. M., Muresan, M.-S., Bălăcescu, L., Lisencu, C. I., & Irimie, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123711 · Cited by 158 · see citing works

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities

Zhang, X., Wu, T., Cai, X., Dong, J., Xia, C., Zhou, Y., Ding, R., Yang, R., Tan, J., Zhang, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795972 · Cited by 162 · see citing works

Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer

Okita, A., Takahashi, S. I., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., & Ishioka, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24617 · Cited by 156 · see citing works

The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases

Andratschke, N. H., Alheid, H., Allgäuer, M., Becker, G., Blanck, O., Boda‐Heggemann, J., Brunner, T. B., Duma, M. N., Gerum, S., Gückenberger, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4191-2 · Cited by 154 · see citing works

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

Xu, R., Muro, K., Morita, S., Iwasa, S., Han, S., Wang, W., Kotaka, M., Nakamura, M., Ahn, J. B., Deng, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30140-2 · Cited by 152 · see citing works

Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines

Cavestro, G. M., Mannucci, A., Balaguer, F., Hampel, H., Kupfer, S. S., Repici, A., Bianchi, A. S., Seppälä, T. T., Valentini, V., Boland, C. R., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.12.006 · Cited by 151 · see citing works

The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor

Xie, Q., Chen, P., Hu, W., Sun, P., He, W., Jiang, C., Kong, P., Liu, S., Chen, H., Yang, Y., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1638-9 · Cited by 148 · see citing works

Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer

Montroni, I., Ugolini, G., Saur, N. M., Spinelli, A., Rostoft, S., Millán, M., Wolthuis, A. M., Daniels, I. R., Hompes, R., Penna, M., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.08.003 · Cited by 145 · see citing works

Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)

Araghi, M., Arnold, M., Rutherford, M. J., Guren, M. G., Cabasag, C. J., Bardot, A., Ferlay, J., Tervonen, H. E., Shack, L., Woods, R. R., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320625 · Cited by 146 · see citing works

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Van Cutsem, E., Martinelli, E., Cascinu, S., Sobrero, A., Banzi, M., Seitz, J.-F., Barone, C., Ychou, M., Peeters, M., Brenner, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0072 · Cited by 142 · see citing works

Therapeutic landscape and future direction of metastatic colorectal cancer

Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 146 · see citing works

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 139 · see citing works

Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group

deSouza, N. M., Liu, Y., Chiti, A., Oprea‐Lager, D. E., Gebhart, G., BEERS, B. E. V., Herrmann, K., & Lecouvet, F. E. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.012 · Cited by 138 · see citing works

The current status of treatment for colorectal cancer in China

Zhang, Y., Chen, Z., & Li, J. (2017) · Medicine · doi:10.1097/md.0000000000008242 · Cited by 135 · see citing works

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies

Vogel, A., Hofheinz, R., Kubicka, S., & Arnold, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.007 · Cited by 134 · see citing works

Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy

Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122 · see citing works

Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases

Wang, C., Sandhu, J. S., Ouyang, C., Ye, J., Lee, P. P., & Fakih, M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.18416 · Cited by 134 · see citing works

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02696-8 · Cited by 132 · see citing works

Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival

Calandri, M., Yamashita, S., Gazzera, C., Fonio, P., Veltri, A., Bustreo, S., Sheth, R. A., Yevich, S. M., Vauthey, J., & Odisio, B. C. (2018) · European Radiology · doi:10.1007/s00330-017-5273-2 · Cited by 130 · see citing works

Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study

Majano, S. B., Girolamo, C. D., Rachet, B., Maringe, C., Guren, M. G., Glimelius, B. L. G., Iversen, L. H., Schnell, E. A., Lundqvist, K., Christensen, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30646-6 · Cited by 132 · see citing works

The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers

Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 128 · see citing works

Current Targeted Therapy for Metastatic Colorectal Cancer

Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 130 · see citing works

CD44v6 engages in colorectal cancer progression

Ma, L., Dong, L., & Chang, P. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1265-7 · Cited by 128 · see citing works

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,509 · see citing works

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)

Gómez‐España, M. A., Gallego-Plazas, J., González‐Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliú, J., & Vera, R. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02002-w · Cited by 61 · see citing works

Stage IV Colorectal Cancer Management and Treatment

Dominguez, O. H., Yılmaz, S., & Steele, S. R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052072 · Cited by 122 · see citing works

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 35 · see citing works

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer ; A JSMO - ESMO initiative

Yoshino, T. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy355.001 · Cited by 4 · see citing works